Harout Semerjian: I am incredibly proud to have worked alongside such passionate individuals
GlycoMimetics announced on LinkedIn:
“Today, we announced we are initiating a strategic review and corporate restructuring at GlycoMimetics.
We would like to thank our innovative and driven team for their dedication to improving the lives of patients. We are grateful for their hard work progressing uproleselan and GMI-1687.
If your company is looking for great talent across biotech functions, please contact [email protected] to connect with our exceptional team members.
To learn more read the full press release here.”
Harout Semerjian shared the post by GlycoMimetics post on LinkedIn and added:
“With today’s announcement, we unfortunately will say goodbye to many talented colleagues. I am incredibly proud to have worked alongside such passionate individuals. If your company is hiring, please let me know or reach out to the email below. I would be happy to connect you with these highly qualified professionals.”
Source: GlycoMimetics/LinkedIn and Harout Semerjian/LinkedIn
Harout Semerjian is the President, Chief Executive Officer and Director at GlycoMimetics, Inc. He is also the Director at Biotechnology Innovation Organization. Previously, he served as the President, Chief Executive Officer and Director at Immunomedics, Inc. in 2020. He has also held the position of Chief Commercial Officer and Executive VP at Ipsen SA and Ipsen Pharma SAS. Harout Semerjian holds an MBA from Queen’s University and Cornell University. He completed his undergraduate degree at Lebanese American University.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023